• Users Online: 1015
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO EDITOR
Year : 2020  |  Volume : 3  |  Issue : 1  |  Page : 147-148

Authors' reply to Chandrasekharan et al. and Abbas


Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India

Date of Submission01-Feb-2020
Date of Acceptance01-Feb-2020
Date of Web Publication24-Feb-2020

Correspondence Address:
Vanita Noronha
Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai - 400 012, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/CRST.CRST_48_20

Get Permissions


How to cite this article:
Kapoor A, Noronha V, Patil VM, Joshi A, Menon N, Prabhash K. Authors' reply to Chandrasekharan et al. and Abbas. Cancer Res Stat Treat 2020;3:147-8

How to cite this URL:
Kapoor A, Noronha V, Patil VM, Joshi A, Menon N, Prabhash K. Authors' reply to Chandrasekharan et al. and Abbas. Cancer Res Stat Treat [serial online] 2020 [cited 2020 Mar 30];3:147-8. Available from: http://www.crstonline.com/text.asp?2020/3/1/147/279155



We thank Chandrasekharanet al. and Abbas for their interest and comments on our article and the accompanying editorial.[1],[2] Chandrasekharan et al.[1] have highlighted an interesting point that the pretreatment neutrophil-to-lymphocyte ratio (NLR) appears to select patients who respond poorly to immunotherapy.[3] Such a simple biomarker if proven to be of predictive significance in larger studies, will definitely prove to be of clinical importance for selecting patients for immunotherapy. Mezquita et al. found that the lung immune prognostic index which is based on a combination of pretreatment NLR >3 and lactate dehydrogenase level greater than the upper limit of normal correlated with worse outcomes for immunotherapy, suggesting that it may serve as an important marker for the same.[4] This appears intriguing especially when clinicians are in dire need for more biomarkers for predicting the efficacy of immunotherapy. Another important point which has been considered is the significance of concurrent use of antibiotics with steroids in some patients. The patients who did not receive antibiotics had significantly better overall survival in our study.[5]

Abbas[2] has pointed out that the survival in our study was inferior to that reported in the pivotal immunotherapy trials. This is noteworthy because our study provided real-world data on consecutive patients who were offered immunotherapy. Our study gives information regarding the actual outcomes of patients who received immunotherapy as part of standard care; all these patients may not have been eligible for the clinical trials which had relatively strict selection criteria. The results of these pivotal trials may have overestimated the survival benefits from the particular therapy.[6] About 40% of the patients in our study had the Eastern Cooperative Oncology Group performance score of 2 and above. We did not find any difference in survival (both progression-free survival and overall survival) based on the indication of the use of steroids (immune-related adverse effects versus others). Further subgroup analysis would decrease the number of patients in each subgroup precluding any meaningful conclusion. We agree that analyzing a larger database from the real-world scenario will help to lead to firmer conclusions.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Chandrasekharan A, Sreelesh KP, Gangadharan KV. Steroids and immunotherapy: The good, bad, or the ugly? Cancer Res Stat Treat 2020;3:145-6.  Back to cited text no. 1
  [Full text]  
2.
Abbas W. Impact of corticosteroids and antibiotic use during treatment with immune checkpoint inhibitors. Cancer Res Stat Treat 2020;3:146-7.  Back to cited text no. 2
  [Full text]  
3.
Rangarajan B, Abhinav RK. Beyond the tumor and tumor milieu – Factors affecting responses to immunotherapy. Cancer Res Stat Treat 2019;2:224-5.  Back to cited text no. 3
  [Full text]  
4.
Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 2018;4:351-7.  Back to cited text no. 4
    
5.
Kapoor A, Noronha V, Patil VM, Joshi A, Menon N, Abraham G, et al. Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with solid neoplasms: A real-world experience from a tertiary cancer center. Cancer Res Stat Treat 2019;2:204-8.  Back to cited text no. 5
  [Full text]  
6.
Banna GL, Passiglia F, Colonese F, Canova S, Menis J, Addeo A, et al. Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. Crit Rev Oncol Hematol 2018;129:27-39.  Back to cited text no. 6
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed63    
    Printed0    
    Emailed0    
    PDF Downloaded13    
    Comments [Add]    

Recommend this journal